U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024615) titled 'A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer' on June 09.
Brief Summary: Some people with pancreatic ductal cancer (PDAC) have a protein called Claudin 18.2 (CLDN18.2) in their tumor. ASP2138 is thought to work by binding to CLDN18.2 and a protein on a type of immune cell called a T-cell. The T-cell "tells" the immune system to attack the tumor. This study is for people with resectable PDAC. Resectable means that the tumor can be removed by surgery.
In this study, adults with resectable PDAC will receive an ASP2138 injection just below the skin (subcutaneous) a fe...